. . "(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone"@en . "* 8.34 L/h [healthy male receiving a 1-mg IV bolus]"@en . "43% to 49%"@en . "* 27 L [intravenous bolus administration to healthy male volunteers]"@en . . . . . . . "L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide"@en . . "investigational"@en . . . . "Leuprorelinum"@en . . "Bioavailability by subcutaneous administration is comparable to that by intravenous administration."@en . . . "~3 hours"@en . . . "In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a clinical counterpart of this phenomenon. In early clinical trials with leuprolide acetate doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose."@en . . . . "Excretion in urine"@en . . . . . . . " "@en . "53714-56-0"@en . "Leuprorelina"@en . "For treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty"@en . . . . "PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet"@en . "# Saleh FM, Niel T, Fishman MJ: Treatment of paraphilia in young adults with leuprolide acetate: a preliminary case report series. J Forensic Sci. 2004 Nov;49(6):1343-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15568711 # Geier MR, Geier DA: The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses. 2005;64(5):946-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15780490 # Doraiswamy PM, Xiong GL: Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother. 2006 Jan;7(1):1-10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16370917 # Sequence Information \"Link\":http://www.freepatentsonline.com/EP1790656.html # \"RxMed\":http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20L)/LUPRON%20DEPOT.html"@en . . . . . " "@en . . "Leuprolide"@en . . . "Leuprolide binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion."@en . "Leuprorelin"@en . "approved"@en . "Daniel Kadzimirzs, Gerhard Jas, Volker Autze, \"Solution-Phase Synthesis of Leuprolide and Its Intermediates.\" U.S. Patent US20090005535, issued January 01, 2009."@en . . . "Leuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer's disease."@en . "PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5"@en . "Humans and other mammals"@en . . . "Leuproreline"@en .